Annual EBITDA
$17.90 M
+$155.24 M+113.04%
31 December 2023
Summary:
Krystal Biotech annual earnings before interest, taxes, depreciation & amortization is currently $17.90 million, with the most recent change of +$155.24 million (+113.04%) on 31 December 2023. During the last 3 years, it has risen by +$84.13 million (+127.03%). KRYS annual EBITDA is now at all-time high.KRYS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$36.46 M
+$13.38 M+57.93%
30 September 2024
Summary:
Krystal Biotech quarterly earnings before interest, taxes, depreciation & amortization is currently $36.46 million, with the most recent change of +$13.38 million (+57.93%) on 30 September 2024. Over the past year, it has dropped by -$77.65 million (-68.05%). KRYS quarterly EBITDA is now -68.05% below its all-time high of $114.11 million, reached on 31 December 2023.KRYS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$181.09 M
+$61.09 M+50.91%
30 September 2024
Summary:
Krystal Biotech TTM earnings before interest, taxes, depreciation & amortization is currently $181.09 million, with the most recent change of +$61.09 million (+50.91%) on 30 September 2024. Over the past year, it has increased by +$163.18 million (+911.39%). KRYS TTM EBITDA is now at all-time high.KRYS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KRYS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -68.0% | +911.4% |
| 3 y3 years | +127.0% | +267.2% | +374.0% |
| 5 y5 years | +185.3% | +726.8% | +962.7% |
KRYS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +113.0% | -68.0% | +166.8% | at high | +215.6% |
| 5 y | 5 years | at high | +113.0% | -68.0% | +166.8% | at high | +215.6% |
| alltime | all time | at high | +113.0% | -68.0% | +166.8% | at high | +215.6% |
Krystal Biotech EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $36.46 M(+57.9%) | $181.09 M(+50.9%) |
| June 2024 | - | $23.09 M(+210.9%) | $120.00 M(+98.9%) |
| Mar 2024 | - | $7.42 M(-93.5%) | $60.34 M(+237.0%) |
| Dec 2023 | $17.90 M(-113.0%) | $114.11 M(-563.4%) | $17.91 M(-111.9%) |
| Sept 2023 | - | -$24.63 M(-32.7%) | -$150.76 M(-3.7%) |
| June 2023 | - | -$36.57 M(+4.4%) | -$156.61 M(+5.9%) |
| Mar 2023 | - | -$35.01 M(-35.8%) | -$147.81 M(+7.9%) |
| Dec 2022 | -$137.33 M(+107.4%) | -$54.55 M(+79.0%) | -$137.01 M(+31.4%) |
| Sept 2022 | - | -$30.48 M(+9.7%) | -$104.27 M(+17.7%) |
| June 2022 | - | -$27.78 M(+14.7%) | -$88.60 M(+15.8%) |
| Mar 2022 | - | -$24.21 M(+11.0%) | -$76.52 M(+15.8%) |
| Dec 2021 | -$66.23 M(+118.5%) | -$21.81 M(+47.3%) | -$66.09 M(+22.0%) |
| Sept 2021 | - | -$14.81 M(-5.7%) | -$54.18 M(+11.7%) |
| June 2021 | - | -$15.70 M(+13.9%) | -$48.51 M(+23.8%) |
| Mar 2021 | - | -$13.78 M(+39.3%) | -$39.17 M(+29.2%) |
| Dec 2020 | -$30.32 M | -$9.89 M(+8.3%) | -$30.32 M(+15.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$9.13 M(+43.6%) | -$26.24 M(+18.5%) |
| June 2020 | - | -$6.36 M(+29.1%) | -$22.15 M(+3.7%) |
| Mar 2020 | - | -$4.93 M(-15.3%) | -$21.36 M(+1.7%) |
| Dec 2019 | -$20.99 M(+78.3%) | -$5.82 M(+15.4%) | -$20.99 M(+8.6%) |
| Sept 2019 | - | -$5.04 M(-9.5%) | -$19.33 M(+12.2%) |
| June 2019 | - | -$5.57 M(+22.1%) | -$17.22 M(+22.3%) |
| Mar 2019 | - | -$4.56 M(+9.7%) | -$14.08 M(+19.6%) |
| Dec 2018 | -$11.78 M(+147.9%) | -$4.16 M(+41.7%) | -$11.78 M(+29.4%) |
| Sept 2018 | - | -$2.93 M(+21.0%) | -$9.10 M(+10.2%) |
| June 2018 | - | -$2.42 M(+7.3%) | -$8.26 M(+26.2%) |
| Mar 2018 | - | -$2.26 M(+52.2%) | -$6.54 M(+37.8%) |
| Dec 2017 | -$4.75 M(+316.2%) | -$1.48 M(-28.9%) | -$4.75 M(+22.3%) |
| Sept 2017 | - | -$2.09 M(+193.3%) | -$3.88 M(+83.4%) |
| June 2017 | - | -$712.00 K(+53.4%) | -$2.12 M(+50.7%) |
| Mar 2017 | - | -$464.00 K(-25.0%) | -$1.41 M(+49.3%) |
| Dec 2016 | -$1.14 M | -$619.00 K(+92.2%) | -$941.00 K(+192.2%) |
| Sept 2016 | - | -$322.00 K | -$322.00 K |
FAQ
- What is Krystal Biotech annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Krystal Biotech?
- What is Krystal Biotech quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Krystal Biotech?
- What is Krystal Biotech quarterly EBITDA year-on-year change?
- What is Krystal Biotech TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Krystal Biotech?
- What is Krystal Biotech TTM EBITDA year-on-year change?
What is Krystal Biotech annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of KRYS is $17.90 M
What is the all time high annual EBITDA for Krystal Biotech?
Krystal Biotech all-time high annual earnings before interest, taxes, depreciation & amortization is $17.90 M
What is Krystal Biotech quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of KRYS is $36.46 M
What is the all time high quarterly EBITDA for Krystal Biotech?
Krystal Biotech all-time high quarterly earnings before interest, taxes, depreciation & amortization is $114.11 M
What is Krystal Biotech quarterly EBITDA year-on-year change?
Over the past year, KRYS quarterly earnings before interest, taxes, depreciation & amortization has changed by -$77.65 M (-68.05%)
What is Krystal Biotech TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of KRYS is $181.09 M
What is the all time high TTM EBITDA for Krystal Biotech?
Krystal Biotech all-time high TTM earnings before interest, taxes, depreciation & amortization is $181.09 M
What is Krystal Biotech TTM EBITDA year-on-year change?
Over the past year, KRYS TTM earnings before interest, taxes, depreciation & amortization has changed by +$163.18 M (+911.39%)